Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Medtronic, Inc. (MDT): St. Jude Medical, Inc. (STJ)’s Enlightening New Hope

Page 1 of 2

St. Jude Medical, Inc. (NYSE:STJ)  has been nothing short of great for investors this year, rewarding shareholders with stock gains of 40% since the start of 2013. The company’s sales haven’t shone with quite the same luster, however, as St. Jude Medical, Inc. (NYSE:STJ) ‘s revenue has fallen around 2% over the year’s first six months. It has been a trend with St. Jude and many of the top companies centered around the cardiovascular device space, which have struggled behind a variety of problems besieging the industry lately.

St. Jude Medical, Inc.

However, St. Jude Medical, Inc. (NYSE:STJ) ‘s looking ahead. The company picked up some good news on Thursday for one of its developing businesses full of potential. Is there something brewing behind the scenes at St. Jude Medical, Inc. (NYSE:STJ)  to alleviate this company’s woes?

The temptations of a promising market
Renal denervation is a new field in endoscopy used to treat the growing problem of hypertension. It has attracted the attention of many of the big names in the device industry, and St. Jude Medical, Inc. (NYSE:STJ) ‘s no exception. On Thursday, the company picked up European CE Mark approval for the next generation of its EnligHTN renal denervation system, which St. Jude Medical, Inc. (NYSE:STJ)  claimed in its press release is more than five times faster in its usage than its first generation of the device.

St. Jude can’t afford to slow down in this industry. So far, renal denervation hasn’t scratched the big dollars of the company’s financial reports, and the global device market for this ailment was estimated at less than $100 million in 2012.

However, analysts are expecting the renal denervation device market to heat up to between $2 billion and $3 billion by 2021. The global hypertension market in all boasts a huge population, with more than 75 million patients in the U.S. alone. Capturing even a small slice of that would provide a huge boost to St. Jude’s lagging cardiovascular device sales.

However, rivals are hard on St. Jude’s heels here — and in Medtronic, Inc. (NYSE:MDT)‘s case, already out in front. Medtronic, Inc. (NYSE:MDT)’s Symplicity renal denervation system picked up CE Mark approval back in 2010 and has emerged as an early leader in this field. Meanwhile, Boston Scientific Corporation (NYSE:BSX)‘s charging ahead after it purchased renal denervation developer Vessix Vascular last year for up to $425 million in all. Vessix’s V2 system has already won approvals in Europe and Australia, keeping Boston in line with St. Jude and Medtronic in this promising market. Covidien plc (NYSE:COV)‘s OneShot renal denervation device also won CE Mark approval in 2012, and the company launched the device in Europe, Asia, and other international markets early this year.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!